Sunday, May 3, 2009

Patent Office rejects Gilead's application for crystalline form of HBV drug

The Indian Patent Office has rejected patent protection for Gilead Sciences Inc's crystalline form of adefovir dipivoxil, a new form of its Hepatitis B drug Hepsera, in a pre-grant opposition filed by Ranbaxy Laboratories

The details can be read here.

No comments: